BRPI0409206C1 - composições compreendendo cepas de lactobacillus em combinação com tanino e uso das referidas cepas de lactobacillus - Google Patents

composições compreendendo cepas de lactobacillus em combinação com tanino e uso das referidas cepas de lactobacillus

Info

Publication number
BRPI0409206C1
BRPI0409206C1 BRPI0409206A BRPI0409206A BRPI0409206C1 BR PI0409206 C1 BRPI0409206 C1 BR PI0409206C1 BR PI0409206 A BRPI0409206 A BR PI0409206A BR PI0409206 A BRPI0409206 A BR PI0409206A BR PI0409206 C1 BRPI0409206 C1 BR PI0409206C1
Authority
BR
Brazil
Prior art keywords
lactobacillus strains
tannin
combination
compositions
strains
Prior art date
Application number
BRPI0409206A
Other languages
English (en)
Inventor
Jeppsson Bengt
Molin Göran
Ahrné Siv
Original Assignee
Probi Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Probi Ab filed Critical Probi Ab
Priority to BR122018068574-3A priority Critical patent/BR122018068574B1/pt
Publication of BRPI0409206A publication Critical patent/BRPI0409206A/pt
Publication of BRPI0409206B1 publication Critical patent/BRPI0409206B1/pt
Publication of BRPI0409206B8 publication Critical patent/BRPI0409206B8/pt
Publication of BRPI0409206C1 publication Critical patent/BRPI0409206C1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7032—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/18—Carboxylic ester hydrolases (3.1.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/01—Carboxylic ester hydrolases (3.1.1)
    • C12Y301/0102—Tannase (3.1.1.20)
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/11—Lactobacillus
    • A23V2400/169—Plantarum
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/225—Lactobacillus
    • C12R2001/25—Lactobacillus plantarum
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/822—Microorganisms using bacteria or actinomycetales
    • Y10S435/853—Lactobacillus
    • Y10S435/857—Lactobacillus plantarum

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Nutrition Science (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)

Abstract

composições compreendendo cepas de lactobacillus plantarum em combinação com tanino e cepas de lactobacillus plantarum. a invenção refere-se a uma composição que compreende uma ou mais cepas produtoras de tanase de lactobacillus tendo a capacidade de se aderir à mucosa intestinal humana em combinação com tanino. cepas produtoras de tanase de lactobacillus plantarum são uma delas.
BRPI0409206A 2003-04-04 2004-04-02 composições compreendendo cepas de lactobacillus em combinação com tanino e uso das referidas cepas de lactobacillus BRPI0409206C1 (pt)

Priority Applications (1)

Application Number Priority Date Filing Date Title
BR122018068574-3A BR122018068574B1 (pt) 2003-04-04 2004-04-02 Uso de uma cepa produtora de lactobacillus plantarum de tanase para a preparação de um medicamento para o tratamento profilático ou curativo de lesão por isquemia/reperfusão

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE0300994A SE527555C2 (sv) 2003-04-04 2003-04-04 Anti-inflammatorisk komposition innehållande tannasproducerande Lactobacillusstammar
US46305803P 2003-04-16 2003-04-16
PCT/SE2004/000509 WO2004087893A1 (en) 2003-04-04 2004-04-02 Compositions comprising lactobacillus plantarum strains in combination with tannin and new lactobacillus plantarum strains

Publications (4)

Publication Number Publication Date
BRPI0409206A BRPI0409206A (pt) 2006-03-28
BRPI0409206B1 BRPI0409206B1 (pt) 2018-11-06
BRPI0409206B8 BRPI0409206B8 (pt) 2019-01-22
BRPI0409206C1 true BRPI0409206C1 (pt) 2021-05-25

Family

ID=20290933

Family Applications (2)

Application Number Title Priority Date Filing Date
BRPI0409206A BRPI0409206C1 (pt) 2003-04-04 2004-04-02 composições compreendendo cepas de lactobacillus em combinação com tanino e uso das referidas cepas de lactobacillus
BR122018068574-3A BR122018068574B1 (pt) 2003-04-04 2004-04-02 Uso de uma cepa produtora de lactobacillus plantarum de tanase para a preparação de um medicamento para o tratamento profilático ou curativo de lesão por isquemia/reperfusão

Family Applications After (1)

Application Number Title Priority Date Filing Date
BR122018068574-3A BR122018068574B1 (pt) 2003-04-04 2004-04-02 Uso de uma cepa produtora de lactobacillus plantarum de tanase para a preparação de um medicamento para o tratamento profilático ou curativo de lesão por isquemia/reperfusão

Country Status (18)

Country Link
US (3) USRE46718E1 (pt)
EP (2) EP1613740B1 (pt)
JP (1) JP4731469B2 (pt)
KR (1) KR101122916B1 (pt)
CN (2) CN1798831B (pt)
AT (1) ATE546516T1 (pt)
AU (1) AU2004225568B2 (pt)
BR (2) BRPI0409206C1 (pt)
CA (1) CA2521220C (pt)
DK (1) DK1613740T3 (pt)
ES (2) ES2382930T3 (pt)
PL (2) PL1613740T3 (pt)
PT (1) PT1613740E (pt)
RU (1) RU2356942C2 (pt)
SE (1) SE527555C2 (pt)
SI (1) SI1613740T1 (pt)
WO (1) WO2004087893A1 (pt)
ZA (1) ZA200507938B (pt)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE528382C2 (sv) * 2004-10-05 2006-10-31 Probi Ab Probiotiska lactobacillusstammar för förbättrad vaginal hälsa
SE529199C2 (sv) * 2005-07-05 2007-05-29 Probi Ab Förstärkt absorption
WO2007009187A1 (en) * 2005-07-22 2007-01-25 Tarac Technologies Pty Ltd Polyphenol and probiotic containing nutritional supplement
EP1931363B1 (en) 2005-09-28 2015-11-18 Nordisk Rebalance A/S Treatment of ibd using both probiotic bacteria and fermented cereal as treatment effectors
WO2007040446A1 (en) * 2005-10-06 2007-04-12 Probi Ab Use of lactobacillus for treatment of autoimmune diseases
US8748121B2 (en) * 2006-10-23 2014-06-10 The Trustees Of The University Of Pennsylvania GSH adducts and uses thereof
WO2008075949A1 (en) * 2006-12-20 2008-06-26 Friesland Brands B.V. Modulation of human microsomal triglyceride transfer protein (mtp or mttp) gene expression by food-grade/ingested dietary microorganisms
SI2136825T1 (sl) * 2007-03-01 2014-04-30 Probi Ab Uporaba lactobacillus plantarium za povečanje bakterijske raznolikosti
SE532899C2 (sv) * 2007-06-08 2010-05-04 Probi Ab Förfarande genom fermentering med Lactobacillus plantarum för tillhandahållande av en insulinsvarsreducerande produkt och dess användning farmaceutiskt eller i livsmedel
MX2010011060A (es) * 2008-04-30 2010-11-22 Nestec Sa Productos que comprenden, y usos de, acidos fenolicos descarboxilados derivados a partir de acidos clorogenicos de cafe.
WO2009132887A1 (en) * 2008-04-30 2009-11-05 Nestec S.A. Compositions for preparing a coffee beverage comprising hydrolysed chlorogenic acid
EE05341B1 (et) * 2008-05-13 2010-08-16 O� Tervisliku Piima Biotehnoloogiate Arenduskeskus Isoleeritud mikroorganismi tvi Lactobacillus plantarum Inducia DSM 21379 kui organismi loomulikku kaitsev?imet t?stev probiootik, seda sisaldav toiduaine ja kompositsioon ning mikroorganismi kasutamine rakulist immuunsust t?stva ravimi valmistamisek
EP2210504A1 (en) * 2009-01-27 2010-07-28 Nestec S.A. Composition comprising chicoric acid and/or derivatives thereof
EP2210505A1 (en) * 2009-01-27 2010-07-28 Nestec S.A. Composition comprising caftaric acid and/or derivatives thereof
JP2013507394A (ja) * 2009-10-09 2013-03-04 プロセラ インコーポレイテッド 自閉症スペクトル障害と診断されたヒトにおいて自閉症スペクトル障害に関連する少なくとも一つの症状を低減するための、ペディオコッカス属を含む組成物及び方法
AU2010334993B2 (en) 2009-12-22 2015-07-09 Probi Ab Non-fermented compositions comprising a cereal based fraction and a probiotic and uses thereof
TWI401086B (zh) * 2010-07-20 2013-07-11 Univ China Medical 胚芽乳酸桿菌及其用途
ITMI20110793A1 (it) 2011-05-09 2012-11-10 Probiotical Spa Ceppi di batteri probiotici e composizione sinbiotica contenente gli stessi destinata alla alimentazione dei neonati.
JP6033290B2 (ja) 2011-06-10 2016-11-30 株式会社アモーレパシフィックＡｍｏｒｅｐａｃｉｆｉｃ Ｃｏｒｐｏｒａｔｉｏｎ チャノキ葉から分離した新規なラクトバチルス・プランタラム
KR101295444B1 (ko) * 2011-12-22 2013-08-09 웅진식품주식회사 신규한 홍삼 발효용 미생물, 이를 이용한 홍삼 발효액 및 홍삼 발효 음료
TWI463986B (zh) 2012-08-29 2014-12-11 Univ China Medical 胚芽乳酸桿菌ｃｍｕ９９５菌株之新用途
US11173170B2 (en) 2014-11-05 2021-11-16 Optibiotix Limited Prebiotic composition and its methods of production
CN108064158B (zh) * 2014-11-25 2021-12-21 帝斯曼知识产权资产管理有限公司 用作益生菌的Lactobillus和用于评估对试剂如益生菌的免疫应答的血细胞群
RU2600445C1 (ru) * 2015-09-21 2016-10-20 Федеральное государственное бюджетное образовательное учреждение высшего образования "Московская государственная академия ветеринарной медицины и биотехнологии - МВА имени К.И. Скрябина" (ФГБОУ ВО МГАВМиБ - МВА имени К.И. Скрябина) Способ биоиндикации состояния двухстворчатых моллюсков в условиях техногенного загрязнения среды обитания
GB201600975D0 (en) 2016-01-19 2016-03-02 Probi Ab Novel strain of probiotic bacteria and compositions and uses thereof
ITUA20162013A1 (it) 2016-03-24 2017-09-24 Probiotical Spa Composizione a base di batteri lattici per il trattamento contemporaneo di infezioni vaginali di origine micotica e batterica.
IT201700057079A1 (it) * 2017-05-25 2018-11-25 Probiotical Spa Batterioterapia a base di composizioni batteriche per il trattamento di malattie neurodegenerative
KR102770563B1 (ko) * 2018-06-18 2025-02-21 프로비 에이비 락토바실러스 플란타룸 조성물 및 이의 용도
CA3116415A1 (en) * 2018-11-05 2020-05-14 MarvelBiome, Inc. Microbial compositions comprising ellagitannin and methods of use
WO2020181096A1 (en) * 2019-03-05 2020-09-10 The Texas A&M University System Combinations of tannase and probiotic formulations and methods of use for improving tannin metabolism
GB201908154D0 (en) * 2019-06-07 2019-07-24 Probi Ab Lactobacillus compositions and uses thereof
CN111500655B (zh) * 2020-03-19 2021-03-05 北京北农科技有限公司 一种五倍子单宁制备新工艺
CN112386614B (zh) * 2020-11-25 2022-11-08 天津科技大学 植物乳杆菌ma2在制备预防或改善阿尔茨海默症药物或食品方面中的应用
KR102390694B1 (ko) * 2021-07-13 2022-04-29 한국식품연구원 락티플란티바실러스 파라플란타룸 WiKim0130을 포함하는 암의 예방, 개선 또는 치료용 조성물
CN114107161B (zh) * 2021-11-15 2023-06-20 泸州老窖股份有限公司 一种混合驯化菌株降解石榴皮生产鞣花酸的方法
CN113980858B (zh) * 2021-11-18 2023-05-02 上海植酵盛生物科技有限公司 一株产高活性单宁酶的植物乳杆菌yl399及其在制备党参发酵饲料中的应用
CN117384879B (zh) * 2023-01-13 2024-04-30 中国农业科学院茶叶研究所 一种适应茶汁体系的耐酸单宁酶制备方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2453763A1 (fr) 1979-04-14 1980-11-07 Teves Gmbh Alfred Regulateur de force de freinage a deux circuits, comportant un piston d'arret actionnable hydrauliquement
JPS5785326A (en) 1980-11-14 1982-05-28 Asahi Glass Co Ltd Stabilization of flon
JPS6425726A (en) * 1987-04-24 1989-01-27 Yuutoku Yakuhin Kogyo Kk Agent for eliminating active oxygen free radical
SE463796B (sv) * 1988-03-09 1991-01-28 Carl Erik Albertsson Foerfarande foer framstaellning av en naeringskomposition och daervid framstaelld naeringskomposition
SE469875C (sv) * 1991-07-25 1997-04-14 Probi Ab Stam av tarmkoloniserande Lactobacillus samt komposition för profylax eller behandling av infektioner i magtarmkanalen
JP3459837B2 (ja) 1992-05-12 2003-10-27 太陽化学株式会社 生菌粉末
JP4127863B2 (ja) * 1993-03-04 2008-07-30 太陽化学株式会社 腸内環境改善組成物
SE9501056D0 (sv) * 1995-03-23 1995-03-23 Probi Ab Epithelial adherent lactobacilli
SE9501719D0 (sv) * 1995-05-09 1995-05-09 Probi Ab Pharmaceutical composition
SE510753C2 (sv) * 1997-08-05 1999-06-21 Probi Ab Användning av en stam av Lactobacillus för tillverkning av ett läkemedel för reduktion av fibrinogenhalten i blod
US6830750B1 (en) * 1998-10-01 2004-12-14 Probi Ab Reduction of oxidative stress factors with Lactobacillus plantarum
FR2789580A1 (fr) * 1999-02-12 2000-08-18 Oreal Compositions cosmetiques antisolaires a base d'un melange synergique de filtres et utilisations
SE523771C2 (sv) * 1999-05-21 2004-05-18 Probi Ab Sportdryck innehållande mikronäringsämnen i kombination med levande laktobaciller
SE0004124D0 (sv) 2000-11-10 2000-11-10 Probi Ab New use
KR100549193B1 (ko) * 2002-10-23 2006-02-02 (주)바이오뉴트리젠 인삼 및 폴리페놀계 물질 또는 바이오플라보노이드계 물질을 포함하는 식물의 분말 또는 추출물을 포함하는 항비만용 식품

Also Published As

Publication number Publication date
CN1798831B (zh) 2011-05-18
PL1613740T3 (pl) 2012-07-31
EP2163162A1 (en) 2010-03-17
ES2382930T3 (es) 2012-06-14
CA2521220C (en) 2014-05-27
PL2163162T3 (pl) 2020-02-28
USRE46718E1 (en) 2018-02-20
CN1798831A (zh) 2006-07-05
WO2004087893A1 (en) 2004-10-14
KR20060005356A (ko) 2006-01-17
HK1162937A1 (en) 2012-09-07
BRPI0409206B8 (pt) 2019-01-22
PT1613740E (pt) 2012-05-28
US20060257384A1 (en) 2006-11-16
ZA200507938B (en) 2007-03-28
KR101122916B1 (ko) 2012-06-13
RU2005134223A (ru) 2006-03-10
BRPI0409206A (pt) 2006-03-28
AU2004225568B2 (en) 2008-02-14
SI1613740T1 (sl) 2012-09-28
CN102210717B (zh) 2013-02-06
ATE546516T1 (de) 2012-03-15
AU2004225568A1 (en) 2004-10-14
HK1094004A1 (en) 2007-03-16
BR122018068574B1 (pt) 2021-10-26
JP2006521817A (ja) 2006-09-28
EP1613740B1 (en) 2012-02-22
SE527555C2 (sv) 2006-04-11
CN102210717A (zh) 2011-10-12
SE0300994L (sv) 2004-10-05
WO2004087893A9 (en) 2006-03-30
US7507572B2 (en) 2009-03-24
CA2521220A1 (en) 2004-10-14
BRPI0409206B1 (pt) 2018-11-06
EP1613740A1 (en) 2006-01-11
JP4731469B2 (ja) 2011-07-27
USRE44400E1 (en) 2013-07-30
SE0300994D0 (sv) 2003-04-04
RU2356942C2 (ru) 2009-05-27
ES2751101T3 (es) 2020-03-30
EP2163162B1 (en) 2019-08-07
DK1613740T3 (da) 2012-05-21

Similar Documents

Publication Publication Date Title
BRPI0409206C1 (pt) composições compreendendo cepas de lactobacillus em combinação com tanino e uso das referidas cepas de lactobacillus
BRPI0410503A (pt) uso da ivermectina para a fabricação de uma composição farmacêutica tópica, composição tópica e uso da composição
ATE478120T1 (de) Thermoplastische zusammensetzungen
BRPI0516437A (pt) utilização de uma quantidade eficaz de pelo menos um microorganismo, processo de tratamento cosmético, composição cosmética e/ou dermatológica e composição para absorção oral
ATE517125T1 (de) ANTIKÖRPER GEGEN ßDEATH RECEPTOR 4ß (DR4) UND DEREN VERWENDUNGEN
NO20043259L (no) Bindingsproteiner som biosensorer
EP1409544A4 (en) HUMAN DR4 ANTIBODIES AND ITS APPLICATIONS
BR0206689A (pt) Combinação de probióticos, e, uso desta
ECSP055725A (es) Formulaciones nutricionales que contienen sustancias simbióticas
BR9900972A (pt) Uso de uma associação de lactobacilos para a preparação de uma composição para tratamento de vaginoses e vaginites, e composições farmacêuticas assim preparadas.
WO2004011611A3 (en) Taci antibodies and uses thereof
BR0116032A (pt) imidazoquinolinas substituìdas com sulfonamido éster
BR9709881A (pt) "formulação de borracha de nitrila mole"
BRPI0510785A (pt) método para fabricar uma folha contìnua compósita, estrutura compósita elástica, peça de roupa, e, dispositivo de incontinência
DK0760848T3 (da) Lactobacillusstammer af menneskelig oprindelse, deres sammensætninger og anvendelse deraf
IL173692A0 (en) Bacterial strains, compositions including same and probiotic use thereof
BRPI0416292A (pt) composições estabilizadas compreendendo probióticos
ITMI20042189A1 (it) Composizione a base di batteri probiotici e suo uso nella prevenzione e-o nel trattamento di patologie e-o infezioni respiratorie e nel miglioramento della funzionalita' intestinale
EP1545599A4 (en) IMMUNOGENIC COMPOSITIONS AND ITS DIAGNOSTIC AND THERAPEUTIC USES
BR0013110A (pt) Forma oral de administração contendo microorganismos probióticos
BRPI0407176B8 (pt) composições compreendendo uma ou mais cepas de bifidobacterium e seus usos
BR0309421A (pt) Composições de proteìna associada com corpo oleoso e métodos de uso destas para reduzir o risco de doença cardiovascular
ITRM20040166A1 (it) Ceppi batterici lab con proprieta' probiotiche e composizioni che contengono gli stessi.
EP1555250A3 (de) Schlichtezusammensetzung
WO2003061611A3 (fr) Composition cosmetique longue tenue comprenant un materiau pro-adhesif et un compose diffusant separes

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B15K Others concerning applications: alteration of classification

Ipc: A61K 31/35 (2006.01), A23L 33/135 (2016.01), A61K

B15K Others concerning applications: alteration of classification

Ipc: C12N 1/20 (2006.01), A61K 31/35 (2006.01), A61K 35

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 06/11/2018, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 06/11/2018, OBSERVADAS AS CONDICOES LEGAIS. (CO) REFERENTE A RPI 2496 DE 06/11/2018,QUANTO AO QUADRO REIVINDICATORIO.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 02/04/2004 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 21A ANUIDADE.

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 02/04/2024

B21H Decision of lapse of a patent or of a certificate of addition of invention cancelled [chapter 21.8 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 21.6 NA RPI NO 2822 DE 04/02/2025 POR TER SIDO INDEVIDA.